Tempest Therapeutics, Inc. (TPST): restructuring charge — Tempest Therapeutics cuts 21 of 26 full-time staff, initiates strategic review

Tempest Therapeutics, Inc.

Workforce reduced by 21 of 26 full-time employees, effective April 30, 2025.
Estimated $1.5M in cash severance and benefit costs, mostly in Q2 2025.
Key affected employees to transition to consulting agreements.
Company initiated process to explore strategic alternatives to extend capital resources.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Tempest Therapeutics, Inc. announced a restructuring with charges of approximately $1.5 million (21 of 26 full-time employees).

Type: restructuring
Charge: approximately $1.5 million
Headcount: 21 of 26 full-time employees

Exact text from the filing

that key employees within this group will transition to consulting agreements and continue to be available to the Company. The Company estimates that it will incur approximately $1.5 million of cash expenditures, consisting primarily of one-time severance payments, benefits and other related costs (excluding non-cash charges associated with equity-based

View on SEC.gov

6 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Tempest Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-085773

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.